Abstract
Diabetic kidney disease (DKD) is a major complication of diabetes mellitus (DM) and the leading cause of end-stage kidney disease (ESKD) worldwide. A significant number of drugs have been clinically investigated for the treatment of DKD. However, a large proportion of patients still develop end-stage kidney disease unstoppably. As a result, new effective therapies are urgently needed to slow down the progression of DKD. Recently, there is increasing evidence that targeted drug delivery strategies such as large molecule carriers, small molecule prodrugs, and nanoparticles can improve drug efficacy and reduce adverse side effects. There is no doubt that targeted drug delivery strategies have epoch-making significance and great application prospects for the treatment of DKD. In addition, the proximal tubule plays a very critical role in the progression of DKD. Consequently, the purpose of this paper is to summarize the current understanding of proximal tubule cell-targeted therapy, screen for optimal targeting strategies, and find new therapeutic approaches for the treatment of DKD.
Funder
Hunan Provincial Natural Science Foundation for Outstanding Youth
Scientific Research Fund of Hunan Provincial Health Commission
Natural Science Foundation of China
The Second Xiangya Hospital of Central South University
Subject
Drug Discovery,Pharmaceutical Science,Molecular Medicine
Reference128 articles.
1. Trends in end-stage kidney disease in Shanghai, China;Chen;Kidney Int.,2019
2. Disease burden and challenges of chronic kidney disease in North and East Asia;Wang;Kidney Int.,2018
3. Global, Regional, and National Burden of Diabetes-Related Chronic Kidney Disease From 1990 to 2019;Deng;Front. Endocrinol.,2021
4. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): A randomised, double-blind, placebo-controlled trial;Pollock;Lancet Diabetes Endocrinol.,2019
5. Mineralocorticoid receptor antagonists in diabetic kidney disease—Mechanistic and therapeutic effects;Bakris;Nat. Rev. Nephrol.,2022
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献